RA Capital Management 13F holdings, Q2 2009
Holdings as of June 30, 2009 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 16 US equity positions worth $106.5m in its Q2 2009 13F filing. The largest position was GILD at 15.8% of the reported book, followed by ARDEA BIOSCIENCES INC and VRTX. Against the Q1 2009 filing, it opened 8 new positions, added to 2 and reduced 5 among the top 16 holdings.
What did RA Capital Management own in Q2 2009? Top 16 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2009 |
|---|---|---|---|---|---|---|---|
| 1 | GILD GILEAD SCIENCES INC | Healthcare | 15.8% | $16.9m | 360,000 | – | new |
| 2 | ARDEA BIOSCIENCES INC | 14.5% | $15.5m | 984,670 | -15% | reduced | |
| 3 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 11.5% | $12.3m | 341,244 | 1% | added |
| 4 | DENDREON CORP | 9.4% | $10.0m | 401,040 | 192% | added | |
| 5 | SEQUENOM INC | 7.6% | $8.1m | 2,070,800 | -74% | reduced | |
| 6 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 7.0% | $7.5m | 90,000 | – | new |
| 7 | PHARMASSET INC | 6.7% | $7.2m | 636,658 | -16% | reduced | |
| 8 | ALXN ALEXION PHARMACEUTICALS INC | 6.6% | $7.0m | 170,000 | – | new | |
| 9 | CUBIST PHARMACEUTICALS INC | 5.2% | $5.5m | 300,260 | 0% | held | |
| 10 | GENZYME CORP | 5.0% | $5.3m | 95,000 | – | new | |
| 11 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 3.7% | $3.9m | 250,000 | – | new |
| 12 | AMAG AMAG PHARMACEUTICALS INC | 3.1% | $3.3m | 60,000 | -80% | reduced | |
| 13 | OREXIGEN THERAPEUTICS INC | 1.1% | $1.2m | 227,300 | – | new | |
| 14 | ENTEROMEDICS INC | 1.1% | $1.2m | 347,119 | -58% | reduced | |
| 15 | OSI PHARMACEUTICALS INC | 0.9% | $988.0k | 35,000 | – | new | |
| 16 | ALLOS THERAPEUTICS INC | 0.8% | $829.0k | 100,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.